Silence Therapeutics Q1 net loss $15M; Phase 2 PV trial on track for August 2026 topline

Silence Therapeutics plc

2026-Q1 EPS reported -$0.11 revenue$422,000

Net loss of $15.0M ($0.11 per share) vs $28.5M ($0.20) a year ago; revenue from AstraZeneca collaboration $0.4M.
Cash, cash equivalents & short-term investments at $70.1M as of March 31, 2026.
R&D expenses fell to $9.1M from $20.8M, primarily due to zerlasiran Phase 3 readiness completed in 2025.
Phase 2 SANRECO trial of divesiran for polycythemia vera ongoing; topline results expected August 2026.
Phase 1 abstracts for divesiran (EHA) and SLN312/AZD1705 (EAS) accepted for upcoming congress presentations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Silence Therapeutics plc reported the first quarter ended March 31, 2026 results: revenue $0.4 million, net income Net loss was $15.0 million, or $0.11 basic and diluted net loss per share, EPS $0.11 basic and diluted net loss per share.

Period: the first quarter ended March 31, 2026
Revenue: $0.4 million
Net income: Net loss was $15.0 million, or $0.11 basic and diluted net loss per share
EPS: $0.11 basic and diluted net loss per share
Result: reported results

Exact text from the filing

cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1

View on SEC.gov

Browse all earnings releases →

Silence Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001193125-26-210428

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.